Trial Profile

Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadisegliatin (Primary)
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms CATT1
Sponsors vTv Therapeutics LLC

Most Recent Events

20 May 2025 Planned End Date changed from 1 Mar 2026 to 1 Oct 2026.
20 May 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Sep 2026.
15 May 2025 According to a vTv Therapeutics media release, recent amendment to the protocol will help expedite time to both topline data and the initiation of required larger pivotal studies moving company one step closer to the future New Drug Application (NDA) submission.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com